Literature DB >> 27446472

Simple resection of truncal desmoid tumors: A case series.

Yoshihiro Nishida1, Satoshi Tsukushi1, Hiroshi Urakawa1, Shunsuke Hamada1, Eiji Kozawa1, Kunihiro Ikuta1, Naoki Ishiguro1.   

Abstract

Desmoid tumors of the extra-abdominal and abdominal wall have been associated with morbidity due to the aggressive nature of the surgery and high recurrence rates. Surgery that does not cause functional impairment is desired for patients with desmoid tumors. In the present study, among patients with desmoid tumors who were prospectively and consecutively treated with identical conservative treatment with meloxicam, a selected patients of patients were treated with less invasive surgery than wide-resection. Out of 60 patients pathologically diagnosed with desmoid tumors, 9 patients with tumors refractory to conservative treatment and 4 patients who refused to receive this type of treatment were treated with planned simple resection. Subsequently, the clinical outcome of the patients and the mutational status of the catenin β-1 (CTNNB1) gene in the tumors were analyzed. The mean age of the 13 patients that underwent planned simple resection was 39 years, and the tumors were located in the abdominal wall in 6 cases, the chest wall in 4 cases and the neck in 3 cases. All excised specimens were evaluated and positive microscopic margins were identified; however, during the mean follow-up period of 30 months, 12/13 cases, 7 of which had T41A mutations and 5 of which had no mutations (wild-type), did not develop recurrence. Only 1 initial case with an S45F mutation in the CTNNB1 gene developed recurrence. The results of the present prospectively treated with simple resection and retrospectively analyzed study suggest that planned simple resection could serve as a therapeutic modality for extraperitoneal desmoid tumors, particularly truncal ones with a wild-type or T41A mutational status.

Entities:  

Keywords:  CTNNB1; extraperitoneal desmoid; margin positive; meloxicam; simple resection

Year:  2016        PMID: 27446472      PMCID: PMC4950544          DOI: 10.3892/ol.2016.4792

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Is it possible to identify clinically useful prognostic groups for patients with desmoid tumors?

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Eisuke Arai; Naoki Ishiguro
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

2.  Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.

Authors:  M T Ballo; G K Zagars; A Pollack; P W Pisters; R A Pollack
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 3.  Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles.

Authors:  J J Nuyttens; P F Rust; C R Thomas; A T Turrisi
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

4.  Extremity and trunk desmoid tumors: a multifactorial analysis of outcome.

Authors:  N B Merchant; J J Lewis; J M Woodruff; D H Leung; M F Brennan
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

5.  Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor).

Authors:  R Poon; R Smits; C Li; S Jagmohan-Changur; M Kong; S Cheon; C Yu; R Fodde; B A Alman
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

6.  Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.

Authors:  A Gronchi; P G Casali; L Mariani; S Lo Vullo; M Colecchia; L Lozza; R Bertulli; M Fiore; P Olmi; M Santinami; J Rosai
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.

Authors:  Sébastien Salas; Armelle Dufresne; Binh Bui; Jean-Yves Blay; Philippe Terrier; Dominique Ranchere-Vince; Sylvie Bonvalot; Eberhard Stoeckle; Louis Guillou; Axel Le Cesne; Odile Oberlin; Véronique Brouste; Jean-Michel Coindre
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

8.  Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis.

Authors:  Ning Bo; Dahui Wang; Bingbing Wu; Lian Chen
Journal:  Pediatr Dev Pathol       Date:  2012 May-Jun

9.  CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.

Authors:  Chiara Colombo; Rosalba Miceli; Alexander J Lazar; Federica Perrone; Raphael E Pollock; Axel Le Cesne; Henk H Hartgrink; Anne-Marie Cleton-Jansen; Julien Domont; Judith V M G Bovée; Sylvie Bonvalot; Dina Lev; Alessandro Gronchi
Journal:  Cancer       Date:  2013-07-31       Impact factor: 6.860

10.  Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Yoji Shido; Hiroshi Urakawa; Eisuke Arai; Naoki Ishiguro
Journal:  Cancers (Basel)       Date:  2012-02-07       Impact factor: 6.639

View more
  5 in total

1.  Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Authors:  Yoshihiro Nishida; Akira Kawai; Junya Toguchida; Akira Ogose; Keisuke Ae; Toshiyuki Kunisada; Yoshihiro Matsumoto; Tomoya Matsunobu; Kunihiko Takahashi; Kazuki Nishida; Toshifumi Ozaki
Journal:  Int J Clin Oncol       Date:  2019-07-22       Impact factor: 3.402

Review 2.  The Landmark Series: Desmoid.

Authors:  Marco Fiore; Aimee Crago; Rebecca Gladdy; Bernd Kasper
Journal:  Ann Surg Oncol       Date:  2021-01-01       Impact factor: 5.344

3.  Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.

Authors:  Tomohisa Sakai; Yoshihiro Nishida; Shunsuke Hamada; Hiroshi Koike; Kunihiro Ikuta; Takehiro Ota; Naoki Ishiguro
Journal:  Diagn Pathol       Date:  2017-08-29       Impact factor: 2.644

4.  Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.

Authors:  Yoshihiro Nishida; Shunsuke Hamada; Hiroshi Urakawa; Kunihiro Ikuta; Tomohisa Sakai; Hiroshi Koike; Kan Ito; Ryo Emoto; Yuichi Ando; Shigeyuki Matsui
Journal:  Cancer Sci       Date:  2020-09-05       Impact factor: 6.716

5.  Less-invasive fascia-preserving surgery for abdominal wall desmoid.

Authors:  Yoshihiro Nishida; Shunsuke Hamada; Tomohisa Sakai; Kan Ito; Kunihiro Ikuta; Hiroshi Urakawa; Hiroshi Koike; Shiro Imagama
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.